Welcome back to Stockhouse
Member Sign In

Email or Username:

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History


Sector: Healthcare | Sub-Sector: Drug Manufacturers - Major
Alternate Symbol(s):  BIOYF

Biosyent Inc is a life science company engaged in marketing of pharmaceutical products & manufacturing & marketing of non-chemical bio & health-friendly insecticides. It acquires or license products & commercializes technology to health & public safety.
Price: $10.92 | Change: +$0.22 | %Change: +2.06%
Volume: 20,871 | Day High/Low: 11.00/10.80 | 52 Week High/Low: 12.82/3.15
View modes: 
3 stars

New Canadian Exchange "Aequitas Neo Exchange" ......

Given green ight to begin operating March 1,2015. Jos Schmitt , President and CEO of Aequitas, " I think we have an investor crisis. There's a fundamental need for competition, we need exchanges more
5 stars

Health Care Stocks Outpacing the Market......

Link: Cheers and Happy Investing.  rate and reply
0 stars

RE:Note to kingpost on GUD

thanks uchuck.... good points on the staff issues...I do not own this one btw...and have a few other names I like better...that being said though, with two staff their burn is lower... and they more
1 star

Note to kingpost on GUD

Last we heard, said Teal (m.) Linde on BNNTV about 4,5 mnths, ago, GUD has a total of 2-yes,two-employees. Scary, real scary.  rate and reply
3 stars

RE:RE:Could RX be a takeout for GUD ?....

I am predicting this whole sector will consolidate over the next few years, and about 1/2 the companies will disappear..  rate and reply
0 stars

RE:Could RX be a takeout for GUD ?....

Sure if they put up enough cash/stock - at least $200,000,000 minimum is my guess.  rate and reply
5 stars

Could RX be a takeout for GUD ?....

With another $140M (CDN) Cash added to their COH today GUD has the dollars to do it, even with a combination of cash and stock !!! Cheers!  rate and reply
3 stars

Ever Wonder why the TSX Venture continues to tumble......

Nice Read: Cheers!  rate and reply
0 stars

RE:Whenis the next quarter financials release/update?

Q3 was 20 Oct.  Year end will probably be 4 months after so that should put it in late February.  rate and reply
0 stars

Whenis the next quarter financials release/update?

  rate and reply
5 stars

PLI with over 532 million shares now PP for 15 mil more

versus RX 13.9 million shares with impressive mngt positions hmmm. Like RX for short mid and long term, its inventory of growth, and potential takeout. Interesting calculations on this board more
5 stars

RE:Note to KISU"Carpet-Bombing Pharma Names

Keeping an eye on Prometic Life (PLI).  It has surged in the last few days and they just announced a financing for $1.90 - below todays closing of $2.10.  Tomorrow should be interesting for them.  rate and reply
1 star

Note to KISU"Carpet-Bombing Pharma Names

We're near up 5% to-day, hoping we can achieve stature of DND, of course. Had DND, but sold, still hold T.CXR.. Careful with Knight Therapeutics Awhile back, Teal Linde on BNNTV said V.GUD has, more
0 stars

RE:Cipher Rally Has Fissled

I guess I was way off on that call.  RX has gone nowhere (down a bit) and Cipher is up another $2.00.  I guess I should have sold and gone to DND.  Patience wearing thin but of course if I sell RX more
5 stars

What you get for the current $10.10 price

Current underlying earnings are around $.25/share on basically just 3 drugs (the fourth, while launched, isn't really in the financials yet).  Two of these 3 drugs are in their growth phase ( more
0 stars

Is The Paint nearly dry:)

Waiting for the expected Q4 product launch to create a bit of an uptick.  rate and reply
0 stars

RE:RE:Technical Analysis

I think BNN must also be skeptical of technical analysis. The "chart" they used for RX appeared to contain nothing but the monthly close numbers for the past couple of years and the "analyst" more
3 stars

RE:Technical Analysis

I never watch BNN when technical analysts are featured. Technicals, schmenicals.  rate and reply
5 stars

Technical Analysis

Second stock in the clip and good for a laugh. He's not the sharpest stick in the forest, knows nothing about our fundamentals and seemed quite stunned to see that RX was on the VSX with a SP of over more
5 stars

Sector Positions -- Canadian Pharma marketers

RX -- number 1 TRX - number 2 (report next week) PDP - spec position Also like GUD  rate and reply

Private Equity

Own a piece of our private equity marketplace: Limited to 50 members.

Click here to watch video 4

How to invest in private equity without writing a $1 million check.

Click here to watch video 3

Why the wealthy are 23x wealthier than the average investor.

Click here to watch video 2

Private Equity: Find out why it returned 16% p.a. for 10 years.

Click here to watch video 1